, Rev Neurol, vol.168, p.217, 2012.
Their classification, regional behaviour, life history, and surgical end results ,
, BJS, vol.26, issue.104, pp.957-957, 1939.
Report of Four Cases and Review of Literature, Radiol Clin North Am, vol.37, issue.1, pp.89-100, 1999. ,
Surgical management of meningioma en plaque of the sphenoid ridge, Surg Neurol, vol.55, issue.5, pp.265-274, 2001. ,
Relevance of Simpson grading system and recurrence-free survival after surgery for World Health Organization Grade I meningioma, J Neurosurg, 2017. ,
Update on Brain Tumor Imaging: From Anatomy to Physiology, Am J Neuroradiol, 2006. ,
, Appearance of Meningiomas on
, Diffusion-weighted Images: Correlating Diffusion Constants with Histopathologic Findings, Am J Neuroradiol, 2001.
Preoperative subtyping of meningiomas by perfusion MR imaging, Neuroradiology, vol.50, issue.10, p.835, 2008. ,
,
, Nukl Nucl Med, 1994.
PET-study of intracranial meningiomas: correlation with histopathology, cellularity and proliferation rate, Acta Neurochir Suppl, vol.65, pp.108-119, 1996. ,
PET imaging in patients with meningioma-report of the RANO/PET Group, vol.19, pp.1576-87, 2017. ,
URL : https://hal.archives-ouvertes.fr/inserm-02940559
Histological classification and molecular genetics of meningiomas, Lancet Neurol, vol.5, issue.12, pp.1045-54, 2006. ,
, , 2016.
, World Health Organization Classification of Tumors of the Central Nervous System: a summary, Acta Neuropathol (Berl), vol.131, issue.6, pp.803-823, 2016.
High Incidence of Activating TERT Promoter Mutations in Meningiomas Undergoing Malignant Progression, Brain Pathol, vol.24, issue.2, pp.184-193, 2014. ,
EANO guidelines for the diagnosis and treatment of meningiomas, Lancet Oncol, vol.17, issue.9, pp.383-91, 2016. ,
Radiotherapy after surgery for benign cerebral meningioma, Radiother Oncol, vol.71, issue.1, pp.85-90, 2004. ,
Population-based analysis of sporadic and type 2 neurofibromatosis-associated meningiomas and schwannomas, Neurology, vol.54, issue.1, pp.71-77, 2000. ,
Meningiomas may be a component tumor of multiple endocrine neoplasia type 1, Clin Cancer Res Off J Am Assoc Cancer Res, vol.10, issue.3, pp.869-80, 2004. ,
Tumors of the nervous system and pituitary gland associated with atomic bomb radiation exposure, J Natl Cancer Inst, vol.94, issue.20, pp.1555-63, 2002. ,
Epidemiology and etiology of meningioma, J Neurooncol, 2010. ,
Progesterone and estrogen receptors: opposing prognostic indicators in meningiomas, J Neurosurg, vol.105, issue.2, pp.163-73, 2006. ,
The recurrence of supratentorial meningiomas after surgery, Acta Neurochir (Wien), vol.95, issue.1-2, pp.3-5, 1988. ,
The recurrence of intracranial meningiomas after surgical treatment, J Neurosurg, vol.58, issue.1, pp.51-57, 1983. ,
, J Neurol Neurosurg Psychiatry, vol.20, issue.1, pp.22-39, 1957.
A comparison of World Health Organization tumor grades at recurrence in patients with non-skull base and skull base meningiomas, J Neurosurg, vol.112, issue.5, pp.925-958, 2010. ,
Risk factors predicting recurrence in patients operated on for intracranial meningioma. A multivariate analysis, Acta Neurochir ,
Predicting the probability of meningioma recurrence based on the quantity of peritumoral brain edema on computerized tomography scanning, J Neurosurg, vol.91, issue.3, pp.375-83, 1999. ,
Long-term recurrence rates of atypical meningiomas after gross total resection with or without postoperative adjuvant radiation, Neurosurgery, vol.64, issue.1, pp.56-60, 2009. ,
Atypical meningioma: randomized trials are required to resolve contradictory retrospective results regarding the role of adjuvant radiotherapy, J Cancer Res Ther, vol.11, issue.1, pp.59-66, 2015. ,
Combined Proton and Photon ,
, Conformal Radiotherapy for Intracranial Atypical and Malignant Meningioma, Int J Radiat Oncol ? Biol ? Phys, 2009.
, Oct, vol.1, issue.2, pp.399-406
Résultats de la protonthérapie ciblée fractionnée ,
Historical benchmarks for medical therapy trials in surgery-and radiation-refractory meningioma: a RANO review, Neuro-Oncol, 2014. ,
Meningioma and hormonal influences, Climacteric J Int Menopause Soc, 2003. ,
Double-Blind Phase III ,
, Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005, J Clin Oncol, vol.33, issue.34, pp.4093-4101, 2015.
The role of mifepristone in the management of meningiomas: A systematic review of literature, Acta Neurol Scand, vol.67, issue.3, pp.434-440, 1987. ,
Activation of Human Somatostatin Receptor 2 Promotes Apoptosis Through a Mechanism that is Independent from Induction of p53, Cell Physiol Biochem, vol.12, issue.1, pp.31-39, 2002. ,
Direct binding of p85 to sst2 somatostatin receptor reveals a novel mechanism for inhibiting PI3K pathway, EMBO J, 2006. ,
, Sep, vol.6, issue.17, pp.3943-54
Growing vascular endothelial cells express somatostatin subtype 2 receptors, Br J Cancer, vol.85, issue.2, pp.266-72, 2001. ,
Central and peripheral actions of somatostatin on the growth hormone-IGF-I axis, J Clin Invest, vol.114, issue.3, pp.349-56, 2004. ,
Octreotide therapy in meningiomas: in vitro study, clinical correlation, and literature review, J Neurosurg, vol.127, issue.3, pp.660-669, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01478922
Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial, Clin Cancer Res, vol.26, issue.3, pp.552-559, 2020. ,
URL : https://hal.archives-ouvertes.fr/hal-02457059
Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08), Neuro-Oncol, 2009. ,
Phase II Trials of Erlotinib or Gefitinib in Patients with Recurrent Meningioma, J Neurooncol, vol.96, issue.2, p.211, 2010. ,
, Vascular Endothelial Growth Factor
, Basic Fibroblast Growth Factor, and Placenta Growth Factor in Human Meningiomas and Their Relation to Angiogenesis and Malignancy, Neurosurgery, vol.46, issue.4, pp.938-986, 2000.
Meningioma: analysis of recurrence and progression following neurosurgical resection, J Neurosurg, vol.62, issue.1, pp.18-24, 1985. ,
Long-term survival analysis of atypical meningiomas: survival rates, prognostic factors, operative and radiotherapy treatment, Acta Neurochir, 2014. ,
Outcome and survival following primary and repeat surgery for World Health Organization Grade III meningiomas: Clinical article, J Neurosurg ,
, Principe et technique de la tomographie par émission de positons (TEP), vol.1, pp.2-35, 2004.
Cyclotrons and positron emission tomography radiopharmaceuticals for clinical imaging, Semin Nucl Med, vol.22, issue.3, pp.150-61, 1992. ,
Radiobiologic Principles in Radionuclide Therapy, J Nucl Med, vol.46, issue.1, pp.4-12, 2005. ,
General aspects of the cellular response to low-and high-LET radiation, Eur J Nucl Med, vol.28, issue.4, pp.541-61, 2001. ,
Subjecting Radiologic Imaging to the Linear No-Threshold Hypothesis: A Non Sequitur of Non-Trivial Proportion, J Nucl Med, vol.2, issue.1, pp.1-6, 2015. ,
Radiation-induced bystander and systemic effects serve as a unifying model system for genotoxic stress responses, Mutat Res Mutat Res, vol.778, pp.13-22, 2018. ,
Abscopal effects of radiation therapy: A clinical review for the radiobiologist, Cancer Lett, vol.356, issue.1, pp.82-90, 2015. ,
Using immunotherapy to boost the abscopal effect, Nat Rev Cancer, vol.18, issue.5, pp.313-335, 2018. ,
,
, Joint EANM/MIRD Guidelines for Quantitative 177Lu SPECT Applied for Dosimetry of Radiopharmaceutical Therapy, J Nucl Med, vol.57, issue.26, pp.151-62, 2016.
, Dose Response
, Pancreatic Neuroendocrine Tumors Treated with Peptide Receptor Radionuclide Therapy Using 177Lu-DOTATATE, J Nucl Med, vol.56, issue.2, pp.177-82, 2015.
Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands, Eur J Nucl Med, vol.28, issue.7, pp.836-882, 2001. ,
Rat somatostatin sst2(a) and sst2(b) receptor isoforms mediate opposite effects on cell proliferation, Br J Pharmacol, vol.125, issue.8, pp.1630-1633, 1998. ,
Expression of somatostatin receptor mRNA in human meningiomas and their implication in in vitro antiproliferative activity, J Neurooncol, vol.66, issue.1-2, pp.155-66, 2004. ,
Expression of somatostatin receptors (SSTR1-SSTR5) in meningiomas and its clinicopathological significance, Int J Clin Exp Pathol, vol.8, issue.10, pp.13185-92, 2015. ,
Vascular somatostatin receptors in synovium from patients with rheumatoid arthritis, Eur J Pharmacol, vol.271, issue.2-3, pp.371-379, 1994. ,
Expression of somatostatin receptor subtype 2 mRNA in human lymphoid cells, Cell Immunol, vol.181, issue.1, pp.44-53, 1997. ,
, , vol.438, p.9782743014438, 2012.
Synthesis of Target-Specific Radiolabeled Peptides for Diagnostic Imaging ,
, Bioconjug Chem, vol.14, issue.1, pp.3-17, 2003.
Prospective of 68Ga-Radiopharmaceutical Development. Theranostics, vol.4, pp.47-80, 2013. ,
Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, p.68 ,
, Eur J Nucl Med Mol Imaging, vol.37, issue.10, pp.2004-2014, 2010.
Somatostatin receptor imaging with 68Ga DOTATATE PET/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation, 2015. ,
, Apr, vol.35, issue.2, pp.500-516
Detection of pancreatic neuroendocrine tumors (PNET) using semi-quantitative [68Ga]DOTATOC PET in combination with multiphase contrast-enhanced CT, Q J Nucl Med Mol Imaging Off Publ Ital Assoc Nucl Med AIMN Int Assoc Radiopharmacol IAR Sect Soc Of, vol.58, issue.3, pp.310-318, 2014. ,
68Ga-DOTA-TOC uptake in neuroendocrine tumour and healthy tissue: differentiation of physiological uptake and pathological processes in PET/CT, Eur J Nucl Med Mol Imaging, vol.40, issue.4, pp.514-537, 2013. ,
,
, Comparison of 68Ga-DOTATOC-PET/CT and PET/MRI hybrid systems in patients with cranial meningioma: Initial results. Neuro-Oncol, vol.17, pp.312-321, 2015.
Ga-68-DOTA-TATE PET/CT for Discrimination of Tumors of the Optic Pathway, Orbit, vol.34, issue.1, pp.16-22, 2015. ,
, Gallium, vol.68
, DOTATATE PET in meningioma: A reliable predictor of tumor growth rate? Neuro-Oncol, vol.18, pp.1021-1028, 2016.
Intraoperative and postoperative gamma detection of somatostatin receptors in bone-invasive en plaque meningiomas, Neurosurgery, vol.57, issue.1, 2005. ,
URL : https://hal.archives-ouvertes.fr/inserm-00391007
Increased 68Ga-DOTATATE Uptake in PET Imaging Discriminates Meningioma and Tumor-Free Tissue, J Nucl Med, vol.56, issue.3, pp.347-53, 2015. ,
PET imaging of somatostatin receptors using [68GA]DOTA-D-Phe1-Tyr3-octreotide: first results in patients with meningiomas, J Nucl Med Off Publ Soc Nucl Med, vol.42, issue.7, pp.1053-1059, 2001. ,
Contribution of 68Ga-DOTATOC PET/CT to target volume delineation of skull base meningiomas treated with stereotactic radiation therapy, Int J Radiat Oncol Biol Phys, vol.85, issue.1, pp.68-73, 2013. ,
Improved target volume definition for fractionated stereotactic radiotherapy in patients with intracranial meningiomas by correlation of CT, MRI, and [68Ga]-DOTATOC-PET, Int J Radiat Oncol Biol Phys, vol.65, issue.1, pp.222-229, 2006. ,
DOTATOC-PET/CT for meningioma IMRT treatment planning, Radiat Oncol Lond Engl, vol.68, p.56, 2009. ,
Influence of 68Ga-DOTATOC on sparing of normal tissue for radiation therapy of skull base meningioma: differential impact of photon and proton radiotherapy, Radiat Oncol Lond Engl, vol.13, issue.1, p.58, 2018. ,
Integration of PET-imaging into radiotherapy treatment planning for low-grade meningiomas improves outcome, Eur J Nucl Med Mol Imaging, 2019. ,
11C-methionine PET improves the target volume delineation of meningiomas treated with stereotactic fractionated radiotherapy, Int J Radiat Oncol Biol Phys, vol.66, issue.2, pp.339-383, 2006. ,
Localisation of endocrinerelated tumours with radioiodinated analogue of somatostatin, Lancet Lond Engl, vol.1, issue.8632, pp.242-246, 1989. ,
68Ga-DOTATATE Compared with 111In-DTPA-Octreotide and Conventional Imaging for Pulmonary and Gastroenteropancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis, J Nucl Med Off Publ Soc Nucl Med, vol.57, issue.6, pp.872-880, 2016. ,
111In-Pentetreotide Scintigraphy Versus 68Ga-DOTATATE PET: Impact on Krenning Scores and Effect of Tumor Burden, J Nucl Med, vol.60, issue.9, pp.1266-1275, 2019. ,
Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors, N Engl J Med, vol.376, issue.2, pp.125-160, 2017. ,
Peptide receptor radionuclide therapy, Best Pract Res Clin Gastroenterol, vol.19, issue.4, pp.595-616, 2005. ,
Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides, J Nucl Med Off Publ Soc Nucl Med, vol.36, issue.10, pp.1902-1911, 1995. ,
Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship, J Nucl Med Off Publ Soc Nucl Med, vol.46, issue.1, pp.99-106, 2005. ,
Glucocorticoid dependency as a prognostic factor in radiotherapy for cerebral gliomas, Acta Oncol Stockh Swed, vol.28, issue.1, pp.51-56, 1989. ,
Impact of overall corticosteroid exposure during chemoradiotherapy on lymphopenia and survival of glioblastoma patients, J Neurooncol, vol.143, issue.1, pp.129-165, 2019. ,
Will 177Lu-DOTATATE Treatment Become More Effective in Salvage Meningioma Patients, When Boosting Somatostatin Receptor Saturation? A Promising Case on Intraarterial Administration, Cardiovasc Intervent Radiol, vol.42, issue.11, pp.1649-52, 2019. ,
Intraindividual comparison of selective intraarterial versus systemic intravenous 68Ga-DOTATATE PET/CT in patients with inoperable meningioma, Nukl Nucl Med, vol.58, issue.1, pp.23-30, 2019. ,
90Y-DOTATOC as a Therapeutic Option for Complex Recurrent or Progressive Meningiomas, J Nucl Med, vol.56, issue.11, pp.1748-51, 2015. ,
Accurate assessment of long-term nephrotoxicity after peptide receptor radionuclide therapy with (177)Lu-octreotate, Eur J Nucl Med Mol Imaging, vol.41, issue.3, pp.505-515, 2014. ,
The impact of 177Lu-octreotide therapy on 99mTc-MAG3 clearance is not predictive for late nephropathy, Oncotarget, vol.7, issue.27, pp.41233-41274, 2016. ,
Peptide receptor radionuclide therapy with 90Y-DOTATOC in recurrent meningioma, Eur J Nucl Med Mol Imaging, vol.36, issue.9, p.1407, 2009. ,
Forssell-Aronsson E. Radiation-induced up-regulation of somatostatin receptor expression in small cell lung cancer in vitro, Nucl Med Biol, vol.33, issue.7, pp.841-847, 2006. ,
Radiation induces up-regulation of somatostatin receptors 1, 2, and 5 in small cell lung cancer in vitro also at low absorbed doses, Cancer Biother Radiopharm, vol.26, issue.6, pp.759-65, 2011. ,
Somatostatin receptortargeted radionuclide therapy for progressive meningioma: benefit linked to 68Ga-DOTATATE/-TOC uptake, Neuro-Oncol, vol.18, issue.11, pp.1538-1585, 2016. ,
Somatostatin Receptor-Targeted Radiopeptide Therapy with 90Y-DOTATOC and 177Lu-DOTATOC in Progressive Meningioma: Long-Term Results of a Phase II Clinical Trial, J Nucl Med, vol.56, issue.2, pp.171-177, 2015. ,
Long-term results of multimodal peptide receptor radionuclide therapy and fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma, Clin Transl Radiat Oncol, vol.22, pp.29-32, 2020. ,
Combination of peptide receptor radionuclide therapy with fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma, Radiat Oncol Lond Engl, vol.7, p.99, 2012. ,
,
, Radiolabelled Dota-Peptides in Meningioma: From Clinical Demand to Future Applications, Cancers, 2019.
Prevalence of hitherto unknown brain meningioma detected on 68Ga-DOTATATE positron-emission tomography/computed tomography in patients with metastatic neuroendocrine tumor and exploring potential of 177Lu-DOTATATE peptide receptor radionuclide therapy as single-shot treatment approach targeting both tumors, World J Nucl Med, vol.18, issue.2, pp.160-70, 2019. ,
Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study, Eur J Nucl Med Mol Imaging, vol.38, issue.12, pp.2125-2160, 2011. ,
Peptide Receptor Radionuclide Therapy in Patients with Inoperable Meningiomas: Our Experience and Review of the Literature, Cancer Biother Radiopharm, vol.29, issue.5, pp.193-202, 2014. ,
Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma, J Nucl Med Off Publ Soc Nucl Med, vol.47, issue.10, pp.1599-606, 2006. ,
Successful radiopeptide targeting of metastatic anaplastic meningioma: Case report, Radiat Oncol, vol.6, issue.1, p.94, 2011. ,
,
, After Peptide Receptor Radionuclide Therapy with 177Lu-Octreotate, J Nucl Med, vol.54, issue.11, pp.1857-61, 2013.
Treatment with the radiolabeled somatostatin analog, J Clin Oncol Off J Am Soc Clin Oncol, vol.26, issue.13, pp.2124-2154, 2008. ,
Radiation-Induced Vascular Damage in Tumors: Implications of Vascular Damage in Ablative Hypofractionated Radiotherapy (SBRT and SRS), Radiat Res, 2012. ,
Efficacy of Peptide Receptor Radionuclide Therapy for Esthesioneuroblastoma, J Nucl Med Off Publ Soc Nucl Med, 2020. ,
Response of Recurrent High-Grade Glioma to Treatment with 90Y-DOTATOC, J Nucl Med, vol.51, issue.3, pp.397-400, 2010. ,
,
90Y-, and 111In-Labeled Somatostatin Receptor Antagonist OPS201 in Comparison to the Agonist 177Lu-DOTATATE: The Mass Effect, J Nucl Med, vol.58, issue.9, pp.1435-1476, 2009. ,